US Patent Issued to ENB Therapeutics on Sept. 8 for "Treatment of urothelial and kidney cancers by use of endothelin B receptor antagonists" (New York Inventor)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,728,122, issued on Sept. 8, was assigned to ENB Therapeutics Inc. (New York).

"Treatment of urothelial and kidney cancers by use of endothelin B receptor antagonists" was invented by Sumayah Jamal (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers such as urothelial, bladder, and kidney cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent."

The patent was filed on July 17, 2020, ...